Drug Patents Expiring in 2040

1. Drug name - AIRDUO DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173259 TEVA PHARM Drug delivery device with electronics and power management Jul, 2040

(17 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.113MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.232MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription

2. Drug name - AMELUZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11235169 BIOFRONTERA Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device Oct, 2040

(18 years from now)

Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient

Treatment: Topical lesion-directed and field-directed treatment of actinic keratosis of the face and scalp with photodynamic therapy by positioning an illumination device in an appropriate distance and illuminating the treatment area with narrowband red light

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
10% GEL;TOPICAL Prescription

3. Drug name - ARMONAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173259 TEVA PHARM Drug delivery device with electronics and power management Jul, 2040

(17 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH POWDER;INHALATION Discontinued
0.113MG/INH POWDER;INHALATION Discontinued
0.232MG/INH POWDER;INHALATION Discontinued
0.03MG/INH POWDER;INHALATION Discontinued

4. Drug name - EMERPHED

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090278 NEXUS PHARMS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same May, 2040

(17 years from now)

US11241400 NEXUS PHARMS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same May, 2040

(17 years from now)

Drugs and Companies using EPHEDRINE SULFATE ingredient

Treatment: Use of ephedrine sulfate for treating hypotension

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/10ML (5MG/ML) SOLUTION;INTRAVENOUS Prescription

5. Drug name - EPHEDRINE SULFATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869845 ENDO VENTURES Ephedrine compositions and methods Jan, 2040

(17 years from now)

Drugs and Companies using EPHEDRINE SULFATE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/10ML (5MG/ML) SOLUTION;INTRAVENOUS Prescription

6. Drug name - FARXIGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10973836 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction Mar, 2040

(17 years from now)

Drugs and Companies using DAPAGLIFLOZIN ingredient

Treatment: Reduction of the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction and without type ii diabetes

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

7. Drug name - HETLIOZ LQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11202770 VANDA PHARMS INC Liquid tasimelteon formulations and methods of use thereof Dec, 2040

(18 years from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
4MG/ML SUSPENSION;ORAL Prescription

8. Drug name - INGREZZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940141 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Aug, 2040

(17 years from now)

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

Treatment: Treatment of tardive dyskinesia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE CAPSULE;ORAL Prescription
EQ 60MG BASE CAPSULE;ORAL Prescription
EQ 80MG BASE CAPSULE;ORAL Prescription

9. Drug name - LIVMARLI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11229647 MIRUM Methods for treating cholestasis Feb, 2040

(17 years from now)

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 9.5MG BASE/ML SOLUTION;ORAL Prescription

10. Drug name - LUMAKRAS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11236091 AMGEN INC Solid state forms
May, 2040

(17 years from now)

Drugs and Companies using SOTORASIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
120MG TABLET;ORAL Prescription

11. Drug name - MYCAPSSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11141457 AMRYT Oral octreotide therapy and contraceptive methods Dec, 2040

(18 years from now)

Drugs and Companies using OCTREOTIDE ACETATE ingredient

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients while avoiding concomitant administration of levonorgestrel

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE CAPSULE, DELAYED RELEASE;ORAL Prescription

12. Drug name - PROAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173259 TEVA BRANDED PHARM Drug delivery device with electronics and power management Jul, 2040

(17 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.09MG BASE/INH POWDER, METERED;INHALATION Prescription

13. Drug name - QDOLO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103452 ATHENA Tramadol hydrochloride solution Sep, 2040

(17 years from now)

Drugs and Companies using TRAMADOL HYDROCHLORIDE ingredient

Treatment: Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
5MG/ML SOLUTION;ORAL Prescription

14. Drug name - QINLOCK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10966966 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors Aug, 2040

(17 years from now)

US11185535 DECIPHERA PHARMS Amorphous kinase inhibitor formulations and methods of use thereof Dec, 2040

(18 years from now)

Drugs and Companies using RIPRETINIB ingredient

Treatment: Treatment of advanced gastrointestinal stromal tumor in patients having progressed from a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription

15. Drug name - RECORLEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020393 STRONGBRIDGE Methods of treating disease with levoketoconazole Mar, 2040

(17 years from now)

Drugs and Companies using LEVOKETOCONAZOLE ingredient

Treatment: During levoketoconazole dosage titration for the treatment of cushing's syndrome in patients who concomitantly use metformin, monitoring glycemia, kidney function and vitamin b-12 and adjusting dosage of metformin as needed

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription

16. Drug name - SUNOSI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940133 JAZZ Methods of providing solriamfetol therapy to subjects with impaired renal function Mar, 2040

(17 years from now)

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

Treatment: Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in a patient with moderate renal impairment

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE TABLET;ORAL Prescription
EQ 150MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.